Difficulty: Medium
Average Score: 78%
Practice
A 5-year-old boy has systemic juvenile idiopathic arthritis (sJIA) with systemic manifestations including fever, hepatosplenomegaly, and pericarditis. Of the following, the BEST initial treatment for this boy is
Correct answer
B
Rationale
In the case of a 5-year-old boy with systemic juvenile idiopathic arthritis (sJIA) presenting with systemic manifestations such as fever, hepatosplenomegaly, and pericarditis, the BEST initial treatment is systemic glucocorticoids (Option B).
Systemic glucocorticoids are the first-line treatment for sJIA due to their potent anti-inflammatory effects. In this acute systemic inflammatory condition, glucocorticoids can rapidly reduce inflammation and control symptoms like fever, pericarditis, and organomegaly.
NSAIDs (Option A) are commonly used in arthritis, but in sJIA with systemic features, systemic glucocorticoids are preferred for their broader anti-inflammatory action.
TNF-a inhibitors (Option C) and IL-1 antagonists (Option D) are biologic agents used in refractory cases or when glucocorticoids are not effective. They are not typically considered as initial treatments due to their higher cost, route of administration, and potential side effects in pediatric patients.
Educationally, understanding the rationale behind selecting the appropriate initial treatment in sJIA is crucial for pediatric nurses. It highlights the importance of recognizing the specific manifestations of the disease and tailoring treatment to address the underlying inflammatory process effectively while considering the safety and efficacy profiles of different medications in pediatric populations.
Systemic glucocorticoids are the first-line treatment for sJIA due to their potent anti-inflammatory effects. In this acute systemic inflammatory condition, glucocorticoids can rapidly reduce inflammation and control symptoms like fever, pericarditis, and organomegaly.
NSAIDs (Option A) are commonly used in arthritis, but in sJIA with systemic features, systemic glucocorticoids are preferred for their broader anti-inflammatory action.
TNF-a inhibitors (Option C) and IL-1 antagonists (Option D) are biologic agents used in refractory cases or when glucocorticoids are not effective. They are not typically considered as initial treatments due to their higher cost, route of administration, and potential side effects in pediatric patients.
Educationally, understanding the rationale behind selecting the appropriate initial treatment in sJIA is crucial for pediatric nurses. It highlights the importance of recognizing the specific manifestations of the disease and tailoring treatment to address the underlying inflammatory process effectively while considering the safety and efficacy profiles of different medications in pediatric populations.